Icad Inc (ICAD) Noticias

$iCAD Let's Go!

https://www.globenewswire.com/news-release/2024/11/12/2979073/0/en/iCAD-s-ProFound-Detection-Version-4-0-Gains-FDA-Clearance.html

keep watching next two Q ICAD to $15
outlook breast cancer analysis and breast health at finger tip.

Don't miss
buying now means buying at 75% discount from EOY

keep eye on this one. $5 -$10 by 4thQ 24 or 1stQ25
product & service rev and profit margin likely +100% by 4thQ

no - wow not expired
they were slow to catch up and now ready and rapidly getting accepted in the society

wont be surprised if it start dancing soon. 2x 5x 10x even 20x

Book Value Per Share (mrq) 1.23
implied Shares Outstanding 26.54M
Revenue (ttm) 17.94M
Total Cash (mrq) 19.68M
debt 0, SP 1.3
just 40 year old company.
looks interesting but likely expired

Good to be a bumpy ride with this company. The Q&A from last quarter indicated an unevenness in future quarterly revenues which makes me think the next reported quarter won’t be as good as folks think. Guessing the Q ending 9/30 will be much better though.

ICAD under $2

What’s with this company?

BOD voted their executives some very rich pay packages for FY24.

Likely to make up for no bonuses awarded in FY24.

And those looking for an up-and-coming growth name with tremendous potential in the AI space should consider iCAD (NASDAQ: ICAD). The firm uses AI to detect breast cancer more proficiently than mammographies, and it has formed alliances with GE Healthcare (NASDAQ:GEHC), Alphabet (NASDAQ:GOOG,GOOGL), and two of America’s largest owners of clinics that specialize in mammographies.

In my view, iCAD’s current market capitalization of $38 million far undervalues the firm.

On the date of publication, Larry Ramer held long positions in SMCI and ICAD. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.

Larry Ramer has conducted research and written articles on U.S. stocks for 15 years. He has been employed by The Fly and Israel’s largest business newspaper, Globes. Larry began writing columns for InvestorPlace in 2015. Among his highly successful, contrarian picks have been SMCI, INTC, and MGM. You can reach him on Stocktwits at @larryramer.

5 AI Stocks to Buy Before They Skyrocket

?

3 AI-Driven Stocks That Will Be the Next Trillion-Dollar Companies

America’s #1 Top Trader, Eric Fry, just released his latest AI recommendations with trillion-dollar market cap valuations. Learn their names & full backstories in his new report while they’re still considered a bargain. Enter your email below to get your free copy of “3 AI-Driven Stocks That Will Be the Next Trillion-Dollar Companies” and a complimentary subscription to Eric Fry’s Smart Money e-letter. Get your FREE report now!

Submit

SPONSORED HEADLINES

?

5 Artificial Intelligence Stocks to Buy Before They Skyrocket

?

The Top 7 Stocks for 2024

?

ChatGPT IPO Could Shock the World, Make This Move Before the Announcement

?

“America’s Top Trader” Issues A.I. Code Red: Act Now or Miss Out

MORE FROM INVESTORPLACE

?

MARKET ANALYSIS

Why Today’s Inflation-Driven Flush Comes at the Perfect Time

17h ago · By Luke Lango, InvestorPlace Senior Investment Analyst

?

MARKET ANALYSIS

The Quest for Value: Intel vs. India Stocks

18h ago · By Eric Fry, Editor, Fry's Investment Report

?

TODAY'S MARKET

Mizuho Just Raised Its Price Target on Nvidia (NVDA) Stock

18h ago · By Chris MacDonald, InvestorPlace Contributor

 

 

About InvestorPlace

 

Products

 

Contact Us

 

Help

 

Careers

 

Advertise With Us

 

Disclosures & Disclaimers

 

Privacy Policy

 

Terms of Use

 

Ad Choices

 

Do Not Sell My Personal Information

 

Cookie Preferences

 

DMCA Policy

Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes. Copyright © 2024 InvestorPlace Media, LLC. All rights reserved. 1125 N. Charles St, Baltimore, MD 21201.

Looking good

Partnerships keep coming,will pay off soon

During the third quarter, the company generated net proceeds of approximately $1.8 million from the issuance of 958,248 shares of common stock in the aftermarket ATM offerings at a weighted average price of $2.26 per share.

Only one analyst on the call. Now a standalone product line. They are hiring a bunch of new sales reps to try and get back the maintenance business that wasn’t renewed by prior customers. They said they won’t need to raise additional cash but revenue gains are going to be slow over the next year with this really being a 2025 story.

Retracement to lows from summer and getting a bounce now. Good time to start a position imo.

With the sale of Xsoft , expect the company to lose about $1.7 quarterly sales going forward (about $6.8 million annually). However it was never a money maker for them . Someone else will do a better job with the technology.

The Company currently expects to report revenue for the three months ended September 30, 2023 of between $5.4 million and $5.6 million. In addition, the Company expects total operating expenses for such period of between $5.5 million and $5.7 million. These expected results are not final and it is possible they will change upon filing of Form 10-Q on or before November 14, 2023.

Until some of the insiders step up to the plate and purchase their stock (not counting option grants) this is a no go for me right now. Obviously $1.70 is too expensive for even them at this point.

Craig-Hallum Capital is raising money thru the share offering any time the share price rises above 2.

Unfortunately, at some point, IMO they will lower that price ten cents at a time.

Yeah I must have missed it

Was this news even release by icad?

https://www.prnewswire.com/news-releases/simonmed-imaging-implements-3rd-generation-icad-breast-ai-3-0--301867503.html

Artificial Intelligence Mammograms - SimonMed Website https://www.simonmed.com/artificial-intelligence-mammograms/

Your welcome,just have some patience with this one,its gonna make some people alot of money

Got it now. I was thinking most pennies traded on the OTC but your explanation makes more sense.

Thanks!

They call anything under 5 bucks penny stocks these days

I hope this is not a harbinger of things to come, calling ICAD a “penny stock” when it’s $2/share.

first quarter.

Best AI Penny Stocks to Buy Now

10. iCAD, Inc. (NASDAQ:ICAD)

Number of Hedge Fund Holders: 7

iCAD, Inc. (NASDAQ:ICAD) is a medical device manufacturers whose products are used for early detection of breast, prostate and colorectal cancers. iCAD, Inc. (NASDAQ:ICAD) is using AI in its products. For example, iCAD’s ProFound AI® solution is used in cancer detection systems.

As of the end of the first quarter of 2023, 7 hedge funds in Insider Monkey’s database of 943 funds reported having stakes in iCAD, Inc. (NASDAQ:ICAD). The biggest stakeholder of iCAD, Inc. (NASDAQ:ICAD) during this period was George Mccabe’s Portolan Capital Management which owns a $1.1 million stake in the company

Hope the company was able raise some money thru “at the market” sale of stock. About to break thru $2 …could it retrace back below $1.50?

Unfortunately I wouldn’t call a drop from $3.40 to $2.65 in one day “holding up”.

But if you mean from the low six months ago of 1.25 then I see your point. However most of the new names here got in on the July 18 news.

I suspect it will be a several year hold to see how long they stretch out the subscription revenue.

Held up so far.

Sadly I was correct. Company just issued a $100 million at the market offering (from time to time).

They have about 26 million shares outstanding, 60 million authorized. If fully subscribed they will come close to maxing out A/S or double the current OS shares.

They don’t have to issue any shares if they don’t want to but this filing indicates that they need money and they have to have program in place. Cheaper than borrowing money from a bank right now.

The subscription model is going to smooth out the revenues however it is also going to extend the length of time that they recognize those revenues.

Based upon the deferred revenue recognition in the last 10-Q it’s likely that the periods of recognition could last 24-36 months.

They have managed to reduce cash burn by 50% but that was before this large order where the customer makes out great since they don’t have to pay everything up front and they too get to pay over time.

I wonder if management is considering an offering at this point in order to capitalize on the news?

ICAD has legs

Insurers are going to give mammograms a massive pay raise...preventing missed cases and late stage cases will save insurers billions....and this is just in the USA. Breast cancer is a $30b cost to insurers annually here...a quarter of women in this entire country will be better off now. Over 50m mammograms a year from just RF

In just the U.S. this tech can save billions in costlier late stage cancer by finding cancer earlier. Its well worth a few billion bucks to someone if it can save $5b per year...just in America. These mammograms are about to get a massive pay raise from insurers.

I got out two years ago at 11.50 .

Their revenues and profits shrank and forecasts kept getting missed.

I see they have had some turnover at the top. With the newly signed agreement I just wonder what they had to give up in terms of pricing power in order to land this deal?

Some folks also had advanced knowledge of the deal which was executed on June 27 just about when the stock starting moving from the $1.50 level.

its to a point where if you are not using this tech, you won't be able to do a mammogram. the insurers will demand it, one late stage undiagnosed breast cancer can flip a group insurance plan from the black to the red quickly. Can see a company like United buying both RF partners and iCad in a combo deal

Hmmm....might be good for prostate too, don't you think? Same methodology.

1.6M shares available to short,dropping from 2M is a good sign,fee of 1.79% with 3.29%rebate,paying you to short(looks like a bear trap to me)

i can only answer that for sure tomorrow,upper bolie is $3.88(1 min) so its not parabolic anymore,we shall see if ppl see this as a buy opportunity,watch for demand and low supply as a tell,promising future company's can attract institutional buying and run it up big in time,(rare find lately) i have had a few this year 700%-300% winners,this looks like a good one to me with future potential,will depend on the black rock crooks to not steal every penny between bid and ask then short into oblivion or will they buy and rocket it up?

iCad and the radiologists are going to be able to command much high payments from insurers due to this so that the insurers don't get stuck with undiagnosed or late stage breast cancer at a huge cost to them. Worth billions here, likely can be parlayed into other radiology.....

This still worth buying here?

the potential is astronomical!,i worked for a guy who invented a lay down on table with holes in it for boobs to go thru and scanner went around boobs,genius idea instead of painfully crushing them against flat surface to scan

Product validated, so how much is it worth. Based in NH, healthcare mecca in Boston or NY will buy this for billions to see how it can be used in other radiology.

only 25M o/s and float excites me.near 1st float rotation now,could start up halts,433K short(not including those who shorted today)nice long is my plan

potential is huge,1000X revenue with this deal,at least 10Xpps ?,institutions should be getting on soon

ICAD now No 1 on the Barchart Top 10
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc

gaining momentum,getting found

ICAD had nice action today...hod 3.30...